Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma

Gabanella,Francesca; Maftei,Daniela; Colizza,Andrea; Rullo,Emma; Riminucci,Mara; Pasqualucci,Elena; Di Certo,Maria Grazia; Lattanzi,Roberta; Possenti,Roberta; Corsi,Alessandro; Greco,Antonio; De Vincentiis,Marco; Severini,Cinzia; Ralli,Massimo

doi:10.3892/ol.2023.14170

Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma

Authors:
- Francesca Gabanella
- Daniela Maftei
- Andrea Colizza
- Emma Rullo
- Mara Riminucci
- Elena Pasqualucci
- Maria Grazia Di Certo
- Roberta Lattanzi
- Roberta Possenti
- Alessandro Corsi
- Antonio Greco
- Marco De Vincentiis
- Cinzia Severini
- Massimo Ralli
View Affiliations

Affiliations: CNR‑Institute of Biochemistry and Cell Biology, Department of Sense Organs, Sapienza University of Rome, I‑00161 Rome, Italy, Department of Physiology and Pharmacology V. Erspamer, Sapienza University of Rome, I‑00185 Rome, Italy, Department of Sense Organs, Sapienza University of Rome, I‑00161 Rome, Italy, Department of Molecular Medicine, Sapienza University of Rome, I‑00161 Rome, Italy, Department of Systems Medicine, University of Rome Tor Vergata, I‑00173 Rome, Italy
Published online on: November 30, 2023 https://doi.org/10.3892/ol.2023.14170
Article Number: 37

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Laryngeal cancer accounts for one‑third of all head and neck tumors, with squamous cell carcinoma (SCC) being the most predominant type, followed by neuroendocrine tumors. Chromogranins, are commonly used as biomarkers for neuroendocrine tumors, including laryngeal cancer. It has been reported that secretogranin VGF, a member of the chromogranin family, can be also used as a significant biomarker for neuroendocrine tumors. However, the expression and role of VGF in laryngeal carcinomas have not been previously investigated. Therefore, the present study aimed to determine the expression levels of VGF in laryngeal SCC (LSCC). The present study collected tumor tissues, as well as serum samples, from a cohort of 15 patients with LSCC. The results of reverse transcription‑quantitative PCR, western blot analysis and immunofluorescence assays showed that the selective VGF precursor was downregulated in patients with LSCC. Notably, in tumor tissue, the immunoreactivity for VGF was found in vimentin‑positive cells, probably corresponding to T lymphocytes. The current preliminary study suggested that the reduced expression levels of VGF observed in tumor tissue and at the systemic level could sustain LSCC phenotype. Overall, VGF could be a potential biomarker for detecting neoplastic lesions with a higher risk of tumor invasiveness, even in non‑neuroendocrine tumors.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 6:922020. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ferlito A, Silver CE, Bradford CR and Rinaldo A: Neuroendocrine neoplasms of the larynx: An overview. Head Neck. 31:1634–1646. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hunt JL, Barnes L, Triantafyllou A, Gnepp DR, Devaney KO, Stenman G, Halmos GB, Bishop JA, Skálová A, Willems SM, et al: Well-differentiated neuroendocrine carcinoma of the larynx: Confusion of terminology and uncertainty of early studies. Adv Anat Pathol. 26:246–250. 2019. View Article : Google Scholar : PubMed/NCBI
6	Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L and Gregoire V; EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board, : Reprint of ‘Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up’. Oral Oncol. 113:1050422021. View Article : Google Scholar : PubMed/NCBI
7	Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, Fass G, Fisher SG, Laurie SA, Le QT, et al: Use of larynx-preservation strategies in the treatment of laryngeal cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 36:1143–1169. 2018. View Article : Google Scholar : PubMed/NCBI
8	Portela-Gomes GM, Grimelius L, Wilander E and Stridsberg M: Granins and granin-related peptides in neuroendocrine tumours. Regul Pept. 165:12–20. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP and Salton SRJ: The extended granin family: Structure, function, and biomedical implications. Endocr Rev. 32:755–797. 2011. View Article : Google Scholar : PubMed/NCBI
10	Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T and Fuse H: Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 16:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
11	Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE and Peracchi M: Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 105:2072–2078. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kusafuka K, Abe M, Iida Y, Onitsuka T, Fuke T, Asano R, Kamijo T and Nakajima T: Mucosal large cell neuroendocrine carcinoma of the head and neck regions in Japanese patients: A distinct clinicopathological entity. J Clin Pathol. 65:704–709. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lewis JS Jr, Chernock RD and Bishop JA: Squamous and neuroendocrine specific immunohistochemical markers in head and neck squamous cell carcinoma: A tissue microarray study. Head Neck Pathol. 12:62–70. 2018. View Article : Google Scholar : PubMed/NCBI
14	Wang KR, Jia YJ, Zhou SH, Wang QY, Bao YY, Feng ZY, Yao HT and Fan J: Cutaneous and subcutaneous metastases from atypical laryngeal carcinoids: Case report and review of the literature. Medicine (Baltimore). 95:e27962016. View Article : Google Scholar : PubMed/NCBI
15	Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, Possenti R and Levi A: VGF: A novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol. 21:199–219. 2000. View Article : Google Scholar : PubMed/NCBI
16	Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, Torsello A, Bresciani E, Bulgarelli I, Rizzi R, Pavone F, et al: TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci USA. 103:14584–14589. 2006. View Article : Google Scholar : PubMed/NCBI
17	Severini C, Ciotti MT, Biondini L, Quaresima S, Rinaldi AM, Levi A, Frank C and Possenti R: TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation. J Neurochem. 104:534–544. 2008. View Article : Google Scholar : PubMed/NCBI
18	Shimazawa M, Tanaka H, Ito Y, Morimoto N, Tsuruma K, Kadokura M, Tamura S, Inoue T, Yamada M, Takahashi H, et al: An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS. PLoS One. 5:e153072010. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Qin X, Han Y and Li B: VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders. Biomed Pharmacother. 151:1130992022. View Article : Google Scholar : PubMed/NCBI
20	Annaratone L, Medico E, Rangel N, Castellano I, Marchiò C, Sapino A and Bussolati G: Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling. Endocr Pathol. 25:219–228. 2014. View Article : Google Scholar : PubMed/NCBI
21	Matsumoto T, Kawashima Y, Nagashio R, Kageyama T, Kodera Y, Jiang SX, Okayasu I, Kameya T and Sato Y: A new possible lung cancer marker: VGF detection from the conditioned medium of pulmonary large cell neuroendocrine carcinoma-derived cells using secretome analysis. Int J Biol Markers. 24:282–285. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, Westra W, Van Criekinge W and Sidransky D: Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res. 15:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
23	Brait M, Maldonado L, Begum S, Loyo M, Wehle D, Tavora FF, Looijenga LHJ, Kowalski J, Zhang Z, Rosenbaum E, et al: DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br J Cancer. 106:414–423. 2012. View Article : Google Scholar : PubMed/NCBI
24	Brait M, Maldonado L, Noordhuis M, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, et al: Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS One. 8:e708782013. View Article : Google Scholar : PubMed/NCBI
25	Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G and Borson-Chazot F: Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 60:644–652. 2004. View Article : Google Scholar : PubMed/NCBI
26	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Gabanella F, Colizza A, Mottola MC, Francati S, Blaconà G, Petrella C, Barbato C, Greco A, Ralli M, Fiore M, et al: The RNA-binding protein SMN as a novel player in laryngeal squamous cell carcinoma. Int J Mol Sci. 24:17942023. View Article : Google Scholar : PubMed/NCBI
29	Zhou J, Tao D, Xu Q, Gao Z and Tang D: Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol. 8:3150–3154. 2015.PubMed/NCBI
30	Busse S, Steiner J, Micheel J, Dobrowolny H, Mawrin C, Krause TJ, Adamaszek M, Bogerts B, Bommhardt U, Hartig R and Busse M: Age-related increase of VGF-expression in T lymphocytes. Aging (Albany NY). 6:440–453. 2014. View Article : Google Scholar : PubMed/NCBI
31	Busse S, Steiner J, Glorius S, Dobrowolny H, Greiner-Bohl S, Mawrin C, Bommhardt U, Hartig R, Bogerts B and Busse M: VGF expression by T lymphocytes in patients with Alzheimer's disease. Oncotarget. 6:14843–14851. 2015. View Article : Google Scholar : PubMed/NCBI
32	Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi AM, Halban PA, Ferri GL, Possenti R, Schininà ME and Levi A: Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem. 81:565–574. 2002. View Article : Google Scholar : PubMed/NCBI
33	Ferri GL, Noli B, Brancia C, D'Amato F and Cocco C: VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers. J Chem Neuroanat. 42:249–261. 2011. View Article : Google Scholar : PubMed/NCBI
34	Bartolomucci A, Possenti R, Levi A, Pavone F and Moles A: The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes Nutr. 2:169–180. 2007. View Article : Google Scholar : PubMed/NCBI
35	Rindi G, Licini L, Necchi V, Bottarelli L, Campanini N, Azzoni C, Favret M, Giordano G, D'Amato F, Brancia C, et al: Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. J Clin Endocrinol Metab. 92:2811–2815. 2007. View Article : Google Scholar : PubMed/NCBI
36	Hwang W, Chiu YF, Kuo MH, Lee KL, Lee AC, Yu CC, Chang JL, Huang WC, Hsiao SH, Lin SE and Chou YT: Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition. Cancer Res. 77:3013–3026. 2017. View Article : Google Scholar : PubMed/NCBI
37	Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, Kozak CA, Boozer CN, Peng B, McEvoy RC, Good P, et al: Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron. 23:537–548. 1999. View Article : Google Scholar : PubMed/NCBI
38	Liu A and Curran MA: Tumor hypermetabolism confers resistance to immunotherapy. Semin Cancer Biol. 65:155–163. 2020. View Article : Google Scholar : PubMed/NCBI
39	Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al: Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 162:1229–1241. 2015. View Article : Google Scholar : PubMed/NCBI